Should You Buy Zomedica in April?

16
7
Favorite

Should You Buy Zomedica in April?

Motley Fool2021-04-15

Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（7）

Daniel Tay
·2021-04-15
I invest in this stock.. Hold for 2 years
Reply
Like
Report
stormlee
·2021-04-15
Comment & like. Thanks
Reply
2
Report
Fold Replies
- stormlee:
  TQ
  2021-04-15
  Reply
  Report
pakthedude
·2021-04-15
No.
Reply
1
Report
KTX
·2021-04-15
Like and comment
Reply
2
Report
Fold Replies
- KTX:
  Ok
  2021-04-16
  Reply
  Report
- KTX:
  X
  2021-04-15
  Reply
  Report
- aazbhsj:
  like n comment back pls
  2021-04-15
  Reply
  Report
jeff123
·2021-04-15
Buy or sell
Reply
1
Report
Fold Replies
- Jeremyyeojc:
  buy buy
  2021-04-17
  Reply
  Report
Emberix
·2021-04-15
No ???
Reply
Like
Report
chandra
·2021-04-15
Like and comment
Reply
1
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2127029075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-15 16:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2127029075","market":"us","top_or_hot":-1,"title":"Should You Buy Zomedica in April?","media":"Motley Fool","content":"<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZOM","symbol_name":"Zomedica Pharmaceuticals Corp.","start_time":0,"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","article_id":"2127029075","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","pubTimestamp":1618473624,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The stock has been falling sharply in the past month.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"translate_title":"你应该在四月份买Zomedica吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZOM":0.9},"content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":347162227,"gmtCreate":1618476111169,"gmtModify":1704711410684,"author":{"id":"3573623220650432","authorId":"3573623220650432","name":"Daniel Tay","avatar":"https://static.tigerbbs.com/084a34a7e85f0f077a0253b0ee1a1dbc","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":1},"htmlText":"I invest in this stock.. Hold for 2 years&nbsp;","listText":"I invest in this stock.. Hold for 2 years&nbsp;","text":"I invest in this stock.. Hold for 2 years","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347162227","repostId":2127029075,"repostType":4,"repost":{"id":"2127029075","pubTimestamp":1618473624,"share":"https://www.laohu8.com/m/news/2127029075?lang=&edition=full","pubTime":"2021-04-15 16:00","market":"us","language":"en","title":"Should You Buy Zomedica in April?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","media":"Motley Fool","summary":"The stock has been falling sharply in the past month.","content":"<p><b>Zomedica&nbsp;</b>(NYSEMKT:ZOM) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the <b>S&amp;P 500</b> and its 10% gains in the process. At <a href=\"https://laohu8.com/S/AONE.U\">one</a> point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.</p>\n<p>Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b107aa940a92dbe65acac3c08d30e0c\" tg-width=\"700\" tg-height=\"477\"><span>Image source: Getty Images.</span></p>\n<h2>Why are investors so bullish on Zomedica?</h2>\n<p>Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.</p>\n<p>The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.</p>\n<p>Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.</p>\n<h2>The big risk with Zomedica</h2>\n<p>Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.</p>\n<p>Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.</p>\n<p>But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.</p>\n<p>There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.</p>\n<h2>Is Zomedica worth the risk?</h2>\n<p>It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.</p>\n<p>You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.</p>\n<p>In just the past month, Zomedica's stock has nosedived more than 55% (while the S&amp;P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127029075","content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347163335,"gmtCreate":1618475765427,"gmtModify":1704711404539,"author":{"id":"3571959390768435","authorId":"3571959390768435","name":"stormlee","avatar":"https://static.tigerbbs.com/80629ef9648273c0d6465aee66dbd98a","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Comment &amp; like. Thanks&nbsp;","listText":"Comment &amp; like. Thanks&nbsp;","text":"Comment & like. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/347163335","repostId":2127029075,"repostType":4,"repost":{"id":"2127029075","pubTimestamp":1618473624,"share":"https://www.laohu8.com/m/news/2127029075?lang=&edition=full","pubTime":"2021-04-15 16:00","market":"us","language":"en","title":"Should You Buy Zomedica in April?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","media":"Motley Fool","summary":"The stock has been falling sharply in the past month.","content":"<p><b>Zomedica&nbsp;</b>(NYSEMKT:ZOM) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the <b>S&amp;P 500</b> and its 10% gains in the process. At <a href=\"https://laohu8.com/S/AONE.U\">one</a> point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.</p>\n<p>Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b107aa940a92dbe65acac3c08d30e0c\" tg-width=\"700\" tg-height=\"477\"><span>Image source: Getty Images.</span></p>\n<h2>Why are investors so bullish on Zomedica?</h2>\n<p>Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.</p>\n<p>The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.</p>\n<p>Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.</p>\n<h2>The big risk with Zomedica</h2>\n<p>Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.</p>\n<p>Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.</p>\n<p>But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.</p>\n<p>There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.</p>\n<h2>Is Zomedica worth the risk?</h2>\n<p>It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.</p>\n<p>You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.</p>\n<p>In just the past month, Zomedica's stock has nosedived more than 55% (while the S&amp;P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127029075","content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4042397,"gmtCreate":1618476093631,"gmtModify":1680784167063,"authorId":3571959390768435,"author":{"id":3571959390768435,"authorId":3571959390768435,"name":"stormlee","avatar":"https://static.tigerbbs.com/80629ef9648273c0d6465aee66dbd98a","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.07","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347163335,"type":1,"supId":0,"prevId":0,"content":"<u>TQ</u>","text":"<u>TQ</u>","html":"<u>TQ</u>"}],"langContent":"EN"},{"id":347188704,"gmtCreate":1618475240908,"gmtModify":1704711393979,"author":{"id":"3568024136331742","authorId":"3568024136331742","name":"pakthedude","avatar":"https://static.tigerbbs.com/44a39c1d2d81353756d935bfebfebf9e","vip":1,"crmLevel":6,"crmLevelSwitch":1},"htmlText":"No.","listText":"No.","text":"No.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347188704","repostId":2127029075,"repostType":4,"repost":{"id":"2127029075","pubTimestamp":1618473624,"share":"https://www.laohu8.com/m/news/2127029075?lang=&edition=full","pubTime":"2021-04-15 16:00","market":"us","language":"en","title":"Should You Buy Zomedica in April?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","media":"Motley Fool","summary":"The stock has been falling sharply in the past month.","content":"<p><b>Zomedica&nbsp;</b>(NYSEMKT:ZOM) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the <b>S&amp;P 500</b> and its 10% gains in the process. At <a href=\"https://laohu8.com/S/AONE.U\">one</a> point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.</p>\n<p>Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b107aa940a92dbe65acac3c08d30e0c\" tg-width=\"700\" tg-height=\"477\"><span>Image source: Getty Images.</span></p>\n<h2>Why are investors so bullish on Zomedica?</h2>\n<p>Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.</p>\n<p>The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.</p>\n<p>Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.</p>\n<h2>The big risk with Zomedica</h2>\n<p>Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.</p>\n<p>Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.</p>\n<p>But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.</p>\n<p>There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.</p>\n<h2>Is Zomedica worth the risk?</h2>\n<p>It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.</p>\n<p>You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.</p>\n<p>In just the past month, Zomedica's stock has nosedived more than 55% (while the S&amp;P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127029075","content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347117337,"gmtCreate":1618474872029,"gmtModify":1704711386054,"author":{"id":"3571482211918385","authorId":"3571482211918385","name":"KTX","avatar":"https://static.tigerbbs.com/f7d2d6c9788fbae7ed024ed5ba7c58e4","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/347117337","repostId":2127029075,"repostType":4,"repost":{"id":"2127029075","pubTimestamp":1618473624,"share":"https://www.laohu8.com/m/news/2127029075?lang=&edition=full","pubTime":"2021-04-15 16:00","market":"us","language":"en","title":"Should You Buy Zomedica in April?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","media":"Motley Fool","summary":"The stock has been falling sharply in the past month.","content":"<p><b>Zomedica&nbsp;</b>(NYSEMKT:ZOM) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the <b>S&amp;P 500</b> and its 10% gains in the process. At <a href=\"https://laohu8.com/S/AONE.U\">one</a> point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.</p>\n<p>Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b107aa940a92dbe65acac3c08d30e0c\" tg-width=\"700\" tg-height=\"477\"><span>Image source: Getty Images.</span></p>\n<h2>Why are investors so bullish on Zomedica?</h2>\n<p>Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.</p>\n<p>The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.</p>\n<p>Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.</p>\n<h2>The big risk with Zomedica</h2>\n<p>Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.</p>\n<p>Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.</p>\n<p>But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.</p>\n<p>There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.</p>\n<h2>Is Zomedica worth the risk?</h2>\n<p>It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.</p>\n<p>You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.</p>\n<p>In just the past month, Zomedica's stock has nosedived more than 55% (while the S&amp;P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127029075","content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4054687,"gmtCreate":1618587644945,"gmtModify":1680784359898,"authorId":3571482211918385,"author":{"id":3571482211918385,"authorId":3571482211918385,"name":"KTX","avatar":"https://static.tigerbbs.com/f7d2d6c9788fbae7ed024ed5ba7c58e4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347117337,"type":1,"supId":4042451,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":4044159,"gmtCreate":1618493588538,"gmtModify":1680784197600,"authorId":3571482211918385,"author":{"id":3571482211918385,"authorId":3571482211918385,"name":"KTX","avatar":"https://static.tigerbbs.com/f7d2d6c9788fbae7ed024ed5ba7c58e4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347117337,"type":1,"supId":0,"prevId":0,"content":"X","text":"X","html":"X"},{"id":4042451,"gmtCreate":1618476442798,"gmtModify":1680784163539,"authorId":3552739656093163,"author":{"id":3552739656093163,"authorId":3552739656093163,"name":"aazbhsj","avatar":"https://static.tigerbbs.com/25780cc59d031cb888067c1e4030ed8e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347117337,"type":1,"supId":0,"prevId":0,"content":"like n comment back <u>pls</u>","text":"like n comment back <u>pls</u>","html":"like n comment back <u>pls</u>"}],"langContent":"EN"},{"id":347111631,"gmtCreate":1618474365823,"gmtModify":1704711378922,"author":{"id":"3578111079453218","authorId":"3578111079453218","name":"jeff123","avatar":"https://static.tigerbbs.com/d2c71145c4a9a4565a59fc5476086738","vip":1,"crmLevel":4,"crmLevelSwitch":0},"htmlText":"Buy or sell","listText":"Buy or sell","text":"Buy or sell","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/347111631","repostId":2127029075,"repostType":4,"repost":{"id":"2127029075","pubTimestamp":1618473624,"share":"https://www.laohu8.com/m/news/2127029075?lang=&edition=full","pubTime":"2021-04-15 16:00","market":"us","language":"en","title":"Should You Buy Zomedica in April?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","media":"Motley Fool","summary":"The stock has been falling sharply in the past month.","content":"<p><b>Zomedica&nbsp;</b>(NYSEMKT:ZOM) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the <b>S&amp;P 500</b> and its 10% gains in the process. At <a href=\"https://laohu8.com/S/AONE.U\">one</a> point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.</p>\n<p>Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b107aa940a92dbe65acac3c08d30e0c\" tg-width=\"700\" tg-height=\"477\"><span>Image source: Getty Images.</span></p>\n<h2>Why are investors so bullish on Zomedica?</h2>\n<p>Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.</p>\n<p>The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.</p>\n<p>Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.</p>\n<h2>The big risk with Zomedica</h2>\n<p>Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.</p>\n<p>Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.</p>\n<p>But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.</p>\n<p>There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.</p>\n<h2>Is Zomedica worth the risk?</h2>\n<p>It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.</p>\n<p>You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.</p>\n<p>In just the past month, Zomedica's stock has nosedived more than 55% (while the S&amp;P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127029075","content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4059125,"gmtCreate":1618637104021,"gmtModify":1680784426309,"authorId":3578061345924822,"author":{"id":3578061345924822,"authorId":3578061345924822,"name":"Jeremyyeojc","avatar":"https://static.tigerbbs.com/96261aa62716a70270967e52a5bcdd13","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":"93.49%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":347111631,"type":1,"supId":0,"prevId":0,"content":"buy buy","text":"buy buy","html":"buy buy"}],"langContent":"EN"},{"id":347119240,"gmtCreate":1618474185580,"gmtModify":1704711376173,"author":{"id":"3576059087479676","authorId":"3576059087479676","name":"Emberix","avatar":"https://static.tigerbbs.com/9d94e5579207ca95c77231f61dd9c950","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"No ???","listText":"No ???","text":"No ???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347119240","repostId":2127029075,"repostType":4,"repost":{"id":"2127029075","pubTimestamp":1618473624,"share":"https://www.laohu8.com/m/news/2127029075?lang=&edition=full","pubTime":"2021-04-15 16:00","market":"us","language":"en","title":"Should You Buy Zomedica in April?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","media":"Motley Fool","summary":"The stock has been falling sharply in the past month.","content":"<p><b>Zomedica&nbsp;</b>(NYSEMKT:ZOM) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the <b>S&amp;P 500</b> and its 10% gains in the process. At <a href=\"https://laohu8.com/S/AONE.U\">one</a> point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.</p>\n<p>Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b107aa940a92dbe65acac3c08d30e0c\" tg-width=\"700\" tg-height=\"477\"><span>Image source: Getty Images.</span></p>\n<h2>Why are investors so bullish on Zomedica?</h2>\n<p>Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.</p>\n<p>The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.</p>\n<p>Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.</p>\n<h2>The big risk with Zomedica</h2>\n<p>Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.</p>\n<p>Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.</p>\n<p>But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.</p>\n<p>There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.</p>\n<h2>Is Zomedica worth the risk?</h2>\n<p>It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.</p>\n<p>You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.</p>\n<p>In just the past month, Zomedica's stock has nosedived more than 55% (while the S&amp;P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127029075","content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":347110311,"gmtCreate":1618474109733,"gmtModify":1704711374070,"author":{"id":"3578706888157658","authorId":"3578706888157658","name":"chandra","avatar":"https://static.tigerbbs.com/a9aa38a10b67f170337a83ecf01dc8b2","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/347110311","repostId":2127029075,"repostType":4,"repost":{"id":"2127029075","pubTimestamp":1618473624,"share":"https://www.laohu8.com/m/news/2127029075?lang=&edition=full","pubTime":"2021-04-15 16:00","market":"us","language":"en","title":"Should You Buy Zomedica in April?","url":"https://stock-news.laohu8.com/highlight/detail?id=2127029075","media":"Motley Fool","summary":"The stock has been falling sharply in the past month.","content":"<p><b>Zomedica&nbsp;</b>(NYSEMKT:ZOM) has been <a href=\"https://laohu8.com/S/AONE\">one</a> of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the <b>S&amp;P 500</b> and its 10% gains in the process. At <a href=\"https://laohu8.com/S/AONE.U\">one</a> point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.</p>\n<p>Below, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b107aa940a92dbe65acac3c08d30e0c\" tg-width=\"700\" tg-height=\"477\"><span>Image source: Getty Images.</span></p>\n<h2>Why are investors so bullish on Zomedica?</h2>\n<p>Shares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.</p>\n<p>The popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.</p>\n<p>Truforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.</p>\n<h2>The big risk with Zomedica</h2>\n<p>Any time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.</p>\n<p>Not only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.</p>\n<p>But despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.</p>\n<p>There is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.</p>\n<h2>Is Zomedica worth the risk?</h2>\n<p>It is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.</p>\n<p>You may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.</p>\n<p>In just the past month, Zomedica's stock has nosedived more than 55% (while the S&amp;P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Zomedica in April?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Zomedica in April?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-15 16:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ZOM":"Zomedica Pharmaceuticals Corp."},"source_url":"https://www.fool.com/investing/2021/04/14/should-you-buy-zomedica-in-april/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2127029075","content_text":"Zomedica (NYSEMKT:ZOM) has been one of the hottest stocks of 2021, soaring more than 340% this year and dwarfing the S&P 500 and its 10% gains in the process. At one point it was up more than 900%, but it has been losing steam of late. With such extreme volatility in less than four months, this is a stock that investors should be careful with and take a closer look at before making an investment decision.\nBelow, I'll look at what has been driving the stock's price this year and assess whether Zomedica is just another meme stock benefiting from a rise in internet fame, or if it is an investment that is actually suitable for your portfolio.\nImage source: Getty Images.\nWhy are investors so bullish on Zomedica?\nShares of Zomedica started picking up steam early in the year, when the company announced on Jan. 4 that it had a new CEO (Robert Cohen) and that its Truforma platform was close to launching. That day, more than 400,000 shares of the stock changed hands. Previously, it wasn't all that common for the stock's daily trading volumes to rise above 100,000.\nThe popularity would continue rising and reach a peak of just under 1.1 million shares on Jan. 11 -- even though there wasn't any groundbreaking news on the day to justify such a movement. That suggests there has been some speculation involved in the stock's impressive rally this year.\nTruforma, which was launched mid-March, is Zomedica's only commercialized product thus far, and so there is still quite a bit of risk involved with the company. However, that sort of thing is common with meme stocks. Retail investors are often willing to bet on a company as long as there is potential for its shares to double or triple in value. And with a modest valuation of around $1 billion, there's plenty of room for that to happen to Zomedica -- if the company's product proves to be successful.\nThe big risk with Zomedica\nAny time you invest in a business that doesn't have proven results, you are taking on considerable risk. On Feb. 26, the company released its year-end results for 2020 and noted that it recorded no revenue for the year and that it was still in its development stage. Although its net loss of $16.9 million was less than the $19.8 million loss it incurred in the previous year, the pressure is going to be on the company to start delivering sales numbers -- and soon.\nNot only are sales crucial to get the business to profitability, but in Zomedica's case, they will also be important to prove that there is strong demand for Truforma. And that could be the case, as the company says the platform allows veterinarians to quickly obtain samples from patients to rapidly assess conditions such as hyperthyroidism and euthyroid sick syndrome.\nBut despite what the company or its salespeople may say about the product, it is going to come down to whether veterinarians see value in it, and the sure-fire way to determine that is through Zomedica's sales numbers. On March 16, Zomedica announced its first commercial sale of the Truforma platform. Although that's an important milestone for the business, it is now off to the races to see how many of the products it can sell.\nThere is certainly lots of potential for Zomedica if the product is a success, as pet ownership has been on the rise amid the pandemic. Spending on pets in 2020 totaled $103.6 billion, which was 8.3% higher than the prior-year tally of $95.7 billion. Typically, the industry averages a growth rate of between 3% and 4%.\nIs Zomedica worth the risk?\nIt is one thing to invest in risky stocks that are incurring losses or struggling to grow their sales, but to buy stock of a company that has just started generating revenue takes it to another level. With plenty of other growth stocks out there to invest in that already have successful products, Zomedica might not be worth the risk.\nYou may miss out on some profits by waiting to buy the stock, but you will also minimize the potential that you'll incur significant losses if you invest and the product underperforms. And if Truforma proves to be a winner, there will still be plenty of time to invest in Zomedica.\nIn just the past month, Zomedica's stock has nosedived more than 55% (while the S&P 500 has increased 5%), as investors have been moving away from speculative investments. With no guarantee that the decline is over, investors are likely better off steering clear of Zomedica, at least until there are some sales numbers to assess.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":16,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}